To explore the clinical effect of sodium tanshinone ⅡA sulfonate injection combined with esmolol in the treatment of unstable angina pectoris.

A total of 196 patients with unstable angina pectoris admitted to Changqing District People's Hospital of Jinan from May 2017 to March 2018 were divided into observation group (98 cases) and control group (98 cases) according to the treatment plans. The control group received esmolol treatment on the basis of routine treatment, while the observation group received tanshinone II A sulfonate sodium injection combined with esmolol treatment on the basis of routine treatment. The clinical effect, frequency of angina attack, duration of angina pectoris and incidence of myocardial infarction were observed and compared between the two groups.

The total effective rate was 69.39% (68/98) in the control group and 93.85% (91/98) in the observation group, and the difference was statistically significant (P<0.05). After 14 days of treatment, the frequency and duration of angina pectoris in both groups were improved compared with those before treatment. The frequency and duration of angina pectoris in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). After 14 days of treatment, the levels of hs-CRP, BNP and MMP-9 in the two groups were lower than those before treatment, while the levels of hs-CRP, BNP and MMP-9 in the observation group were lower than those in the control group (P<0.05). There was no myocardial infarction in the observation group and 11 cases (11.22%) in the control group. There was a significant difference in the incidence of myocardial infarction between two groups (P<0.05).

Sodium tanshinone ⅡA sulfonate injection combined with esmolol can improve the symptoms of unstable angina pectoris and reduce the levels of hs-CRP, BNP and MMP-9 in serum.